Published in Expert Opin Ther Targets on May 25, 2015
Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells. Sci Rep (2016) 0.81
Fibrin matrices enhance the transplant and efficacy of cytotoxic stem cell therapy for post-surgical cancer. Biomaterials (2016) 0.78
Super natural killer cells that target metastases in the tumor draining lymph nodes. Biomaterials (2015) 0.78
A novel cationic lipid with intrinsic antitumor activity to facilitate gene therapy of TRAIL DNA. Biomaterials (2016) 0.77
Electrospun nanofibrous scaffolds increase the efficacy of stem cell-mediated therapy of surgically resected glioblastoma. Biomaterials (2016) 0.76
First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors. Invest New Drugs (2017) 0.76
Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL. Stem Cell Res Ther (2016) 0.75
Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells. Sci Rep (2016) 0.75
Targeting cell death signalling in cancer: minimising 'Collateral damage'. Br J Cancer (2016) 0.75
Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey. Cell Death Dis (2016) 0.75
Marine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL). Mar Drugs (2015) 0.75
Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme. Cancer Biol Ther (2016) 0.75
ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells. Oncotarget (2017) 0.75
JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells. Oncogenesis (2017) 0.75
The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5. Sci Rep (2017) 0.75
Bufalin sensitizes human bladder carcinoma cells to TRAIL-mediated apoptosis. Oncol Lett (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Overview of cell death signaling pathways. Cancer Biol Ther (2005) 4.22
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell (2007) 3.37
Critical role for Daxx in regulating Mdm2. Nat Cell Biol (2006) 2.96
TRAIL and apoptosis induction by TNF-family death receptors. Oncogene (2003) 2.75
P53 and radiation responses. Oncogene (2003) 2.52
Retracted GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive response to nutrient stress. Mol Cell (2009) 2.30
Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med (2013) 2.06
p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol (2013) 2.06
Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol Ther (2003) 1.92
Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol (2004) 1.90
Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Mol Cell Biol (2006) 1.88
BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol (2002) 1.84
Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol (2003) 1.83
Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci U S A (2006) 1.80
Tissue-specific induction of p53 targets in vivo. Cancer Res (2002) 1.79
TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets (2010) 1.65
Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem (2004) 1.59
Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res (2007) 1.58
CARP-2 is an endosome-associated ubiquitin ligase for RIP and regulates TNF-induced NF-kappaB activation. Curr Biol (2008) 1.58
DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol (2005) 1.55
Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell (2004) 1.54
Cell surface Death Receptor signaling in normal and cancer cells. Semin Cancer Biol (2003) 1.54
Restoration of p53 to limit tumor growth. Curr Opin Oncol (2008) 1.52
The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21 (WAF1/CIP1 expression). Cell Cycle (2002) 1.45
Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget (2011) 1.43
Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biol Ther (2009) 1.43
TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest (2008) 1.41
Mcl-1: a gateway to TRAIL sensitization. Cancer Res (2008) 1.41
Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis (2009) 1.40
Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol Ther (2005) 1.38
Activating FOXO3a, NF-kappaB and p53 by targeting IKKs: an effective multi-faceted targeting of the tumor-cell phenotype? Cancer Biol Ther (2004) 1.38
TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther (2008) 1.34
Microarray analysis of p53 target gene expression patterns in the spleen and thymus in response to ionizing radiation. Cancer Biol Ther (2003) 1.32
Protective effects of dietary antioxidants on proton total-body irradiation-mediated hematopoietic cell and animal survival. Radiat Res (2009) 1.31
Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc Natl Acad Sci U S A (2002) 1.30
Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem (2004) 1.29
Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res (2004) 1.28
BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol Cell Biol (2002) 1.28
Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. Cell Cycle (2007) 1.28
Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol (2005) 1.27
Current strategies to target p53 in cancer. Biochem Pharmacol (2010) 1.26
Regulation of programmed cell death by the p53 pathway. Adv Exp Med Biol (2008) 1.25
Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol (2003) 1.25
Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia (2002) 1.24
Restoring p53-dependent tumor suppression. Cancer Biol Ther (2003) 1.24
Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J Biol Chem (2011) 1.23
An integrated, multiparametric flow cytometry chip using "microfluidic drifting" based three-dimensional hydrodynamic focusing. Biomicrofluidics (2012) 1.22
Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res (2004) 1.22
Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol Ther (2007) 1.22
Circulating Tumor Cells and Colorectal Cancer. Curr Colorectal Cancer Rep (2010) 1.21
Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. Cancer Res (2006) 1.20
The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle (2009) 1.18
ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest (2014) 1.16
Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci U S A (2003) 1.16
Differentiation of normal skin and melanoma using high resolution hyperspectral imaging. Cancer Biol Ther (2006) 1.16
What are caspases 3 and 7 doing upstream of the mitochondria? Cancer Biol Ther (2006) 1.16
Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting. J Clin Oncol (2011) 1.15
Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nat Genet (2003) 1.14
ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell Cycle (2015) 1.14
Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis (2003) 1.13
Regulation of the human TRAIL gene. Cancer Biol Ther (2012) 1.12
Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle (2002) 1.12
Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. Proc Natl Acad Sci U S A (2004) 1.10
p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer Res (2006) 1.09
Invincible, but not invisible: imaging approaches toward in vivo detection of cancer stem cells. J Clin Oncol (2008) 1.08
Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle (2011) 1.07
Bioluminescent imaging of TRAIL-induced apoptosis through detection of caspase activation following cleavage of DEVD-aminoluciferin. Cancer Biol Ther (2005) 1.04
ERK and MDM2 prey on FOXO3a. Nat Cell Biol (2008) 1.04
Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biol Ther (2013) 1.03
Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53. Cancer Res (2013) 1.02
Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol Ther (2005) 1.02
Microarray expression profiling of p53-dependent transcriptional changes in an immortalized mouse embryo fibroblast cell line. Cancer Biol Ther (2003) 1.02
Cell cycle checkpoint control mechanisms that can be disrupted in cancer. Methods Mol Biol (2004) 1.02
CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J Biol Chem (2006) 1.01
p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia. J Clin Endocrinol Metab (2005) 1.01
Therapeutic targeting of the p53 pathway in cancer stem cells. Expert Opin Ther Targets (2012) 1.01
TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle (2008) 1.01
BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit. J Biol Chem (2003) 1.00
Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med (2011) 0.99
Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells. Cell Cycle (2007) 0.99
CDK1 stabilizes HIF-1α via direct phosphorylation of Ser668 to promote tumor growth. Cell Cycle (2013) 0.98
Multispectral fluorescence imaging. J Nucl Med (2009) 0.98
Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. Oncogene (2002) 0.98
Caspase 10 levels are increased following DNA damage in a p53-dependent manner. Cancer Biol Ther (2003) 0.97
The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo. Cell Cycle (2011) 0.97
IGFBP-3 regulates esophageal tumor growth through IGF-dependent and independent mechanisms. Cancer Biol Ther (2007) 0.97
Clinical implication of p53 mutation in lung cancer. Mol Biotechnol (2003) 0.96
p53, BRCA1 and breast Cancer chemoresistance. Adv Exp Med Biol (2007) 0.96
Identification and characterization of the cytoplasmic protein TRAF4 as a p53-regulated proapoptotic gene. J Biol Chem (2003) 0.96
Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling. Cancer Biol Ther (2006) 0.95
Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1. Cancer Res (2011) 0.94
Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. Cancer Biol Ther (2011) 0.94